PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
December 8, 2025Blood

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

YKYoungil KohSHSeungryel Han

Discussion

Loading...

Member takes

Overview

Phase 1 trial evaluates safety and anti-tumor activity of CD5-targeted CAR-NK therapy in adults with relapsed NK/T-cell malignancies, indicating favorable safety profile.

Key Points

  • Evaluate the safety and efficacy of GCC2005, an allogeneic CD5-directed CAR-NK therapy, in adults with relapsed/refractory NK/T-cell malignancies.
  • Phase 1 open-label dose-escalation trial enrolling adults with CD5-positive R/R NK/T-cell malignancies.
  • Participants received a lymphodepleting regimen of cyclophosphamide and fludarabine, followed by three weekly infusions of GCC2005.
  • Safety determined by adverse events, maximum tolerated dose, and tolerability including dose-limiting toxicities.
  • No dose-limiting toxicities observed and favorable safety profile with only one transient grade 3 adverse event.
  • Preliminary response showed a 60% objective response rate with 40% complete response and 20% partial response.
  • Further dose escalation planned following ongoing safety monitoring.

Cite This Study

Koh et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d46dhttps://doi.org/10.1182/blood-2025-1043
View Full Paper
Ask AI
Bookmark
Share